Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 184 for “"CRPC"”.
-
GRB10 as a key regulator contributing to the development of castration-resistant prostate cancer
… recurrent castration-resistant prostate cancer (CRPC) commonly occur. Current therapies for CRPC, e.g. next-generation ADT including Enzalutamide and Abiraterone, can extend patients’ lives but are not curative as resistance to their use eventually emerges. As such, there is an urgent need to …
-
Phenotypes and transcriptional regulators of non-luminal epithelial cell identities in castration-resistant prostate cancer.
… develop castration-resistant prostate cancer (CRPC). Targeted therapies can promote lineage plasticity, which is defined as the ability of a cell to alter its identity in response to external pressures. While 70-75% of CRPC restores AR signaling, the remaining 25-30% display lineage plasticity …
-
Tmprss2-Erg Regulation Of Androgen Biosynthetic Enzyme Expression, Dht Synthesis, And Androgen Receptor Activation In Prostate Cancer
… of castration-resistant prostate cancer (CRPC). Several enzymes responsible for androgen biosynthesis have been shown to be overexpressed in CRPC, thus, contributing to CRPC in a castrated environment. Although intratumoral androgen synthesis is thought to contribute to the development and …
-
PORCUPINE’S ROLE IN THE ENHANCEMENT OF ENZALUTAMIDE EFFICACY IN DRUG RESISTANT PROSTATE CANCER
… of castration-resistant prostate cancer (CRPC). Subsequently, this has led to the development of Androgen Signaling Inhibitors (ASI), specifically Enzalutamide (ENZ), which is a direct inhibitor of AR, to clinically manage CRPC. Inevitably, ENZ treatment only provides improvement for …
-
Utilizing catalytic Topo II inhibitor to target reestablished androgen receptor signaling in castration-resistant prostate cancer
… the lethal castration-resistant prostate cancer (CRPC) stage. Defining the mechanisms that promote the reestablishment of AR signaling including the androgen independence is important for therapy development and disease control. UDP-glucuronosyltransferase 2B17 (UGT2B17) is a key enzyme that …
-
TMEFF2 is an epigenetic modulator that promotes androgen independent growth in castration-resistant prostate cancer cells
… castration resistant prostate cancer (CRPC), during which the PCa cells develop the ability to grow in androgen depleted conditions. The androgen receptor (AR) plays a vital role in prostate development and homeostasis, and the deregulation of AR drives PCa tumorigenesis and progression …
-
Beyond Inhibition: Overcoming the Kinase-Independent Functions of PIM1 by Targeted Degradation
… to castration-resistant prostate cancer (CRPC). CRPC is a highly aggressive form of cancer, and the five-year survival rate for CRPC patients is dismal. Current treatment options for CRPC include chemotherapy and targeted agents, but these therapies have not been effective. Thus, new …
-
Determining the role of scavenger receptor class B type I as a source of cholesterol for de novo androgen synthesis in castration-resistant prostate cancer
… for castration-resistant prostate cancer (CRPC) extend life and provide clinical benefit; however, patients develop therapeutic resistance. Persistent androgen signaling in CRPC is maintained in part by intratumoral steroidogenesis from the precursor cholesterol. The high density …
-
Hsp60 Promotes Aggressive Prostate Cancer by Modulating Mitochondrial Function
… to ADT and becomes castrate resistant (CRPC). The most aggressive subset of CRPC appears with altered or deleted tumor suppressors Rb1/p53, and as a result has low/no AR expression. This aggressive phenotype readily metastasizes, displays resistance to chemotherapeutic agents and absence …
-
Genetic Aberrations And Cholesterol Metabolism In Castration-Resistant Prostate Cancer
… of the disease, termed castration-resistant PCa (CRPC), accounts for most PCa mortality. PCa is initially dependent on androgens and androgen receptor signaling (AR) for its growth and proliferation. Hence, most therapies for metastatic PCa are directed at inhibiting this signaling axis through …
-
Macrophages promotion of anti-androgen resistance and lineage plasticity in prostate cancer
… of castration-resistant prostate cancer (CRPC). Lineage plasticity has been identified as a crucial mechanism to promote CRPC. Here we identify macrophages secreted factors drives castration-resistance and promotes lineage plasticity. These factors increased the resistance of PC cells …
-
Dual Inhibition of ATR and DNA-PKcs Radiosensitizes ATM Mutant Prostate Cancer
In advanced castration resistant prostate cancer (CRPC), mutations in the DNA damage response (DDR) gene ataxia telangiectasia mutated (ATM) are common. While poly (ADP-ribose) polymerase inhibitors are approved in this context, their clinical efficacy remains limited. Thus, there is a compelling …
-
Preclinical Development and Mechanistic Studies of miR-34a to Target Aggressive Prostate Cancer
… in its aggressive, castration-resistant form (CRPC), presents a significant clinical challenge due to its resistance to conventional therapies. The heterogeneity of CRPC, characterized by varying androgen receptor (AR) expression and the presence of prostate cancer stem cells (PCSCs), further …
-
The Mechanistic Role of Long Non-coding RNAs in Advanced Prostate Cancer Response to Therapy
… called Castration-Resistant Prostate Cancers (CRPCs). Therapies currently used for CRPC treatment include: the new generation anti-androgen enzalutamide, the taxane cabazitaxel and carboplatin. Despite the prolonged survival resulting from these treatments, CRPC is still incurable. Recent …
-
CDK8 AND CDK19 Mediator Kinases as Novel Targets in Advanced Prostate Cancer
… to castration resistant prostate cancer (CRPC) status, where their growth becomes independent of androgen signaling, through altered androgen receptor (AR) signaling or other genetic or transcriptional changes. Metastatic CRPC remains incurable, and the most potent new drugs prolong …
-
A lifestyle intervention to improve outcomes in men with castrate-resistant prostate cancer
… in men with castrate resistant prostate cancer (CRPC), the terminal phase of the disease. It is not clear how exercise has been implemented in the prostate cancer care pathway and what a successfully implemented exercise programme might look like. Furthermore, the specific treatment and disease …
-
Characterisation and role of SLFN5 in castration resistant prostate cancer
Castration resistant prostate cancer (CRPC) is a currently incurable form of prostate cancer. While varying in different countries, prostate cancer recurrence typically manifests clinically around 12-24 months after androgen deprivation therapy, signifying disease treatment resistance1. Tumour …
-
Computational drug discovery for advanced prostate cancers
… to castration-resistant prostate cancer (CRPC), a lethal subtype that displays universal resistance to standard-of-care (SOC) therapies. Given the current lack of efficacious treatments, survival among CRPC patients remains poor. Therefore, there is an urgent need to develop new treatment …
Page 1 of 10